OPKO Health Inc Q4 2025 Earnings Call: Strategic Divestitures and Promising Pipeline
ByAinvest
Friday, Feb 27, 2026 12:35 am ET1min read
OPK--
OPKO Health Inc reported Q4 2025 earnings, with strong momentum in diagnostics and pharmaceuticals. The company completed the sale of its oncology division, positioned its diagnostics business for profitability, and advanced its Modex pipeline. OPKO has a strong cash position, bolstered by asset sales, partnership payments, and international pharmaceutical business contributions. However, diagnostics revenue declined YoY, and the company reported a consolidated operating loss of $38.3 million and net loss of $31.3 million. Total costs and expenses are expected to be high at $725-$750 million for 2026.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet